Published in N Engl J Med on March 06, 2014
Predicting Prostate Biopsy Results With Biomarkers and mpMRI. (ProBioM) | NCT03730324
Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. J Clin Oncol (2015) 5.00
A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol (2015) 3.08
Prevention and early detection of prostate cancer. Lancet Oncol (2014) 2.94
Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer. Eur Urol (2015) 1.44
Active surveillance for prostate cancer: current evidence and contemporary state of practice. Nat Rev Urol (2016) 1.21
Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer. Prostate Cancer Prostatic Dis (2015) 1.02
The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era. Int J Cancer (2015) 0.98
Conceptualizing overdiagnosis in cancer screening. J Natl Cancer Inst (2015) 0.94
A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result. Prostate Cancer Prostatic Dis (2015) 0.93
Controversies associated with the evaluation of elderly men with localized prostate cancer when considering radical prostatectomy. Int J Clin Oncol (2014) 0.91
Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer. Rev Urol (2015) 0.91
Management of early prostate cancer. N Engl J Med (2014) 0.91
Management of early prostate cancer. N Engl J Med (2014) 0.91
Management of early prostate cancer. N Engl J Med (2014) 0.91
Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagn Pathol (2016) 0.88
Increasing use of observation among men at low risk for prostate cancer mortality. J Urol (2014) 0.88
PROMIS--Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer. Contemp Clin Trials (2015) 0.87
Focal laser ablation for localized prostate cancer: principles, clinical trials, and our initial experience. Rev Urol (2014) 0.87
Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients. PLoS One (2015) 0.87
Applying precision medicine to the active surveillance of prostate cancer. Cancer (2015) 0.85
Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer. J Urol (2015) 0.84
[The 2014 consensus conference of the ISUP on Gleason grading of prostatic carcinoma]. Pathologe (2016) 0.83
Trends and outcome from radical therapy for primary non-metastatic prostate cancer in a UK population. PLoS One (2015) 0.83
How Precisely Can Prostate Cancer Be Managed? Int Neurourol J (2016) 0.83
Postprostatectomy Erectile Dysfunction: A Review. World J Mens Health (2016) 0.81
Comparative analysis of oncologic outcomes for open vs. robot-assisted radical prostatectomy in high-risk prostate cancer. Korean J Urol (2015) 0.81
Active surveillance for prostate cancer. Int J Urol (2015) 0.80
Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening. Clin Cancer Res (2015) 0.80
The comparative oncologic effectiveness of available management strategies for clinically localized prostate cancer. Urol Oncol (2016) 0.80
(18)F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy. World J Urol (2015) 0.79
Spotlight on prostate cancer: the latest evidence and current controversies. BMC Med (2015) 0.79
Baseline subject characteristics predictive of compliance with study-mandated prostate biopsy in men at risk of prostate cancer: results from REDUCE. Prostate Cancer Prostatic Dis (2016) 0.78
Screening men at increased risk for prostate cancer diagnosis: Model estimates of benefits and harms. Cancer Epidemiol Biomarkers Prev (2016) 0.78
For which cancers might patients benefit most from expedited symptomatic diagnosis? Construction of a ranking order by a modified Delphi technique. BMC Cancer (2015) 0.78
Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients. Osteoporos Int (2015) 0.78
Prostate Cancer: Utility of Whole-Lesion Apparent Diffusion Coefficient Metrics for Prediction of Biochemical Recurrence After Radical Prostatectomy. AJR Am J Roentgenol (2015) 0.78
A three-protein biomarker panel assessed in diagnostic tissue predicts death from prostate cancer for men with localized disease. Cancer Med (2014) 0.78
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer. Adv Ther (2016) 0.78
MRI-Guided Prostate Biopsy of Native and Recurrent Prostate Cancer. Semin Intervent Radiol (2016) 0.78
Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers. World J Urol (2015) 0.77
Spinal anesthesia does not impact prostate cancer recurrence in a cohort of men undergoing radical prostatectomy: an observational study. Reg Anesth Pain Med (2014) 0.77
Qualitative study on decision-making by prostate cancer physicians during active surveillance. BJU Int (2016) 0.76
Who and when should we screen for prostate cancer? Interviews with key opinion leaders. BMC Med (2015) 0.76
Measures of survival benefit in cancer drug development and their limitations. Urol Oncol (2015) 0.76
Direct Administration of Nerve-Specific Contrast to Improve Nerve Sparing Radical Prostatectomy. Theranostics (2017) 0.76
Surgery and hormonal treatment for prostate cancer and sexual function. Transl Androl Urol (2015) 0.76
RNA biomarkers to facilitate the identification of aggressive prostate cancer. Mol Aspects Med (2015) 0.76
Predictive factors of unfavorable prostate cancer in patients who underwent prostatectomy but eligible for active surveillance. Prostate Int (2014) 0.76
Treatment of localized prostate cancer in elderly patients. Gland Surg (2015) 0.75
Management of early prostate cancer. N Engl J Med (2014) 0.75
Prognostic Factors for Anastomotic Urinary Leakage Following Retropubic Radical Prostatectomy and Correlation With Voiding Outcomes. Medicine (Baltimore) (2016) 0.75
Re: Radical prostatectomy or watchful waiting on early prostate cancer. J Urol (2014) 0.75
Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer. Urol Ann (2016) 0.75
Current technique and results for extended pelvic lymph node dissection during robot-assisted radical prostatectomy. Investig Clin Urol (2016) 0.75
Radical prostatectomy reduces prostate cancer-specific mortality among men with intermediate-grade disease, but provides minimal benefit for men with low-grade and high-grade disease. Evid Based Med (2014) 0.75
Focal Cryotherapy in Low-Risk Prostate Cancer: Are We Treating the Cancer or the Mind? - The Cancer. Int Braz J Urol (2015) 0.75
Words of wisdom. Re: Radical prostatectomy or watchful waiting in early prostate cancer. Eur Urol (2014) 0.75
Targeted prostate biopsy using magnetic resonance imaging-ultrasound fusion. Asian J Androl (2015) 0.75
Treatment patterns for older veterans with localized prostate cancer. Cancer Epidemiol (2015) 0.75
Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry. Cureus (2015) 0.75
More judicious use of expectant management for localized prostate cancer over the past two decades. J Urol (2016) 0.75
Evaluation of a 24-Gene Signature for Prognosis of Metastatic Events and Prostate Cancer-Specific Mortality. BJU Int (2017) 0.75
Are HIV-infected men vulnerable to prostate cancer treatment disparities? Cancer Epidemiol Biomarkers Prev (2014) 0.75
Incidental prostate cancer in transurethral resection of prostate specimens in men aged up to 65 years. Prostate Int (2015) 0.75
Is extended pelvic lymph node dissection for prostate cancer the only recommended option? A systematic over-view of the literature. Turk J Urol (2016) 0.75
The meaning of sampling density in multiple repeat prostate biopsies. Cent European J Urol (2016) 0.75
Radical prostatectomy trumps watchful waiting in early prostate cancer. Commentary on: Radical prostatectomy or watchful waiting in early prostate cancer. Urology (2014) 0.75
Orgasmic Dysfunction after Radical Prostatectomy. World J Mens Health (2017) 0.75
Prostate cancer screening with prostate-specific antigen: A guide to the guidelines. Prostate Int (2016) 0.75
Long-term outcomes of nonpalpable prostate cancer (T1c) patients treated with radical prostatectomy. Prostate Int (2015) 0.75
Comparisons of oncological and functional outcomes among radical retropubic prostatectomy, high dose rate brachytherapy, cryoablation and high-intensity focused ultrasound for localized prostate cancer. Springerplus (2016) 0.75
Words of wisdom. Re: Radical prostatectomy or watchful waiting in early prostate cancer. Eur Urol (2014) 0.75
Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer. Int J Mol Sci (2017) 0.75
Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable? Eur Urol (2016) 0.75
Words of wisdom. Re: radical prostatectomy or watchful waiting in early prostate cancer. Eur Urol (2014) 0.75
CHADS2 scores as a predictor of ischemic stroke after radical prostatectomy. Cancer Med (2015) 0.75
The Treatment of Localized Prostate Cancer in Everyday Practice in Germany. Dtsch Arztebl Int (2016) 0.75
High milk consumption does not affect prostate tumor progression in two mouse models of benign and neoplastic lesions. PLoS One (2015) 0.75
Primary radiotherapy vs conservative management for localized prostate cancer-a population-based study. Prostate Cancer Prostatic Dis (2015) 0.75
Cholesterol Metabolism and Prostate Cancer Lethality. Cancer Res (2016) 0.75
Management of localized prostate cancer: the pendulum swings (back to the middle). Asian J Androl (2014) 0.75
Pelvic Radiotherapy versus Radical Prostatectomy with Limited Lymph Node Sampling for High-Grade Prostate Adenocarcinoma. Prostate Cancer (2016) 0.75
Level of education and mortality after radical prostatectomy. Asian J Androl (2016) 0.75
Unscreened older men diagnosed with prostate cancer are at increased risk of aggressive disease. Prostate Cancer Prostatic Dis (2017) 0.75
Prostate-specific antigen testing: good or bad? Oncologist (2015) 0.75
Prostate cancer: Screening and treatment: where do we go from here? Nat Rev Clin Oncol (2016) 0.75
Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review. J Inflamm (Lond) (2016) 0.75
Outcome of radical retropubic prostatectomy at the Lagos State University Teaching Hospital. Niger Med J (2016) 0.75
Active surveillance in intermediate risk prostate cancer: is it safe? Opinion: No. Int Braz J Urol (2016) 0.75
Primary care follow-up of radical prostatectomy patients: A regional New Zealand experience. Prostate Int (2016) 0.75
ACP Journal Club. Radical prostatectomy reduced long-term mortality more than watchful waiting in early prostate cancer. Ann Intern Med (2014) 0.75
Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection Program. PLoS One (2015) 0.75
Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC. Prostate (2015) 0.75
Phase of care prevalence for prostate cancer in New South Wales, Australia: A population-based modelling study. PLoS One (2017) 0.75
Media reporting of ProtecT: a disconnect in information dissemination? Prostate Cancer Prostatic Dis (2017) 0.75
African-American Prostate Cancer Disparities. Curr Urol Rep (2017) 0.75
Long-term costs and survival of prostate cancer: a population-based study. Int Urol Nephrol (2017) 0.75
Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy. J Surg Oncol (2016) 0.75
Active surveillance of prostate cancer: Current state of practice and utility of multiparametric magnetic resonance imaging. Rev Urol (2017) 0.75
Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions. Eur Urol (2017) 0.75
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2011) 13.30
A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med (2002) 10.64
Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst (2008) 8.62
Quality of life after radical prostatectomy or watchful waiting. N Engl J Med (2002) 6.83
Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA (2000) 6.37
Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol (2011) 5.28
Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate (1983) 3.53
Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial. Eur Urol (2013) 2.84
Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol (2013) 1.97
Staging pelvic lymphadenectomy for carcinoma of the prostate risk versus benefit. J Urol (1980) 1.80
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2005) 16.35
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
A common variant associated with prostate cancer in European and African populations. Nat Genet (2006) 13.47
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2011) 13.30
A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med (2002) 10.64
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med (2010) 8.71
Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst (2008) 8.62
Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med (2012) 7.78
Natural history of early, localized prostate cancer. JAMA (2004) 7.44
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet (2009) 6.91
Quality of life after radical prostatectomy or watchful waiting. N Engl J Med (2002) 6.83
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet (2008) 6.69
The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev (2006) 6.61
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol (2011) 5.28
Long-term colorectal-cancer mortality after adenoma removal. N Engl J Med (2014) 5.05
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ (2014) 4.75
Non-communicable diseases in sub-Saharan Africa: what we know now. Int J Epidemiol (2011) 4.74
The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol (2009) 4.73
Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study. J Clin Oncol (2014) 4.67
Low carbohydrate-high protein diet and incidence of cardiovascular diseases in Swedish women: prospective cohort study. BMJ (2012) 4.05
Talking about death with children who have severe malignant disease. N Engl J Med (2004) 3.92
Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. Lancet (2007) 3.84
A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older: a randomized controlled trial. Arch Intern Med (2009) 3.83
Effect of low doses of ionising radiation in infancy on cognitive function in adulthood: Swedish population based cohort study. BMJ (2004) 3.67
The Swedish Twin Registry in the third millennium: an update. Twin Res Hum Genet (2006) 3.58
Suicide and cardiovascular death after a cancer diagnosis. N Engl J Med (2012) 3.56
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol (2011) 3.45
The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer (2007) 3.44
Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology (2005) 3.40
A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. J Natl Cancer Inst (2003) 3.29
Lung cancer incidence in never smokers. J Clin Oncol (2007) 3.20
Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst (2005) 3.19
Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med (2004) 3.18
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. J Natl Cancer Inst (2011) 2.85
The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer (2002) 2.85
Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial. Eur Urol (2013) 2.84
Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol (2011) 2.76
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet (2009) 2.76